Suppr超能文献

α-1-抗胰蛋白酶缺乏相关肺部疾病的最新进展。

Recent advances in α-1-antitrypsin deficiency-related lung disease.

机构信息

The ADAPT Project, Lung Function and Sleep Department, University Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2WB, UK.

出版信息

Expert Rev Respir Med. 2013 Jun;7(3):213-29; quiz 230. doi: 10.1586/ers.13.20.

Abstract

α-1-antitrypsin deficiency (A1ATD) is an under-recognized hereditary disorder associated with the premature onset of chronic obstructive pulmonary disease. There is considerable heterogeneity in the phenotypic expression of lung disease in A1ATD and the pathophysiology is complex, involving the interaction of multiple pathways. Other genetic factors that may contribute to emphysema risk in A1AT-deficient individuals are beginning to be identified. Methods of monitoring disease progression have evolved, including the use of computed tomography densitometry and biomarkers of disease activity. Progress in the development of novel treatment strategies continues, including the hope for a potential cure through the use of gene therapies. In this article, the authors review the recent advances in this field and outline potential future directions of research in A1ATD.

摘要

α-1-抗胰蛋白酶缺乏症(A1ATD)是一种未被充分认识的遗传性疾病,与慢性阻塞性肺疾病的过早发病有关。A1ATD 患者的肺部疾病表型表现存在相当大的异质性,其病理生理学也很复杂,涉及多种途径的相互作用。其他可能导致 A1AT 缺乏个体发生肺气肿风险的遗传因素也开始被确定。疾病进展的监测方法也在不断发展,包括使用计算机断层扫描密度测定法和疾病活动的生物标志物。新型治疗策略的开发也在不断取得进展,包括通过基因治疗有希望实现潜在的治愈。在本文中,作者回顾了该领域的最新进展,并概述了 A1ATD 未来可能的研究方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验